we have been looking at various ways to improve the use of this antibody in future RIT clinical trials.
A recent study was designed to compare different forms of the murine antibody A5B7 raised against carcinoembryonic antigen (CEA), in order to determine which was the optimal form of the antibody for RIT with the isotopes 131 I and 90 Y (Casey et al, 1996) . Different forms of murine A5B7, namely DFM, F(ab´) 2 , IgG and TFM were synthesized and the functional affinities for CEA were measured under similar conditions using surface plasmon resonance. The study revealed that there was a significantly faster association rate for DFM compared to the other antibody forms. TFM had the slowest dissociation rate; however, this was not significantly different to the divalent antibody forms. This is probably a limitation of the analysis in measuring very slow dissociation rates, since other similar studies have shown clearly that TFM forms of other antibodies show a significant advantage in terms of a slower dissociation rate (King et al, 1994 (King et al, , 1995 . These improved kinetic binding characteristics of cross-linked DFM and TFM may have implications for improved RIT. Biodistribution experiments were also performed in this study to compare similar sized F(ab´) 2 and DFM, and IgG and TFM with both 131 I and 90 Y (Casey et al, 1996) . Results indicated the cross-linked antibodies were highly stable in vivo and that 131 I-DFM and 90 Y-TFM would be the most suitable combinations of antibody and radionuclide for RIT with A5B7.
When selecting new possible candidates for RIT, it is important to consider not only the biodistribution data at various time points after injection, but also quantitative measurement of cumulative radiation dose to tumour and normal tissues with respect to time. Although these dosimetry calculations are based on data generated from a murine model, and can be considered only as estimates, they have previously proved to be useful predictors of toxicity and a guide to the levels of activity that may be administered for RIT (Pedley et al, 1989 (Pedley et al, , 1993 .
The results for this previous study were based only on functional affinity and biodistribution data of both 131 I and 90 Y-labelled F(ab´) 2 , DFM, IgG and TFM. In this second study, detailed dosimetry analysis of the biodistribution data is described in similar comparative experiments. These calculations were useful in predicting the relative radiation doses that could be administered for RIT, and an indication of the resulting toxicity.
MATERIALS AND METHODS

Preparation and characterization of DFM and TFM
Details of preparation and characterization of murine A5B7 DFM and TFM have been described previously in detail by Casey et al (1996) . Briefly F(ab´) 2 was partially reduced with 2-mercaptoethylamine to form Fab´ fragments and produce a free hinge thiol for cross-linking. After desalting to remove free reducing agent, a 2:1 molar excess of Fab´ to dimaleimide CT52 cross-linker and a 3:1 molar excess of Fab´ to trimaleimide CT998 cross-linker was added and the reaction left to proceed at 37°C for 2 h. Final purification of DFM and TFM was performed by high-performance liquid chromatography (HPLC) gel filtration.
Dosimetry
The estimated total doses of β-radiation (per MBq injected) to the blood, tumour and normal tissues were evaluated for each antibody-radiolabel conjugate using the following calculations.
Figures for percentage of injected activity per gram of each tissue (% ia g -1 ) for individual mice were derived by direct measurement of blood and tissues using a γ counter, and the average median value was calculated for each time point as described in detail in a previous publication (Casey et al, 1996) . These values were decay corrected using the following equation and figures shown in Table 1 .
A = A 0 e -λt where λ = Ln2/t 1/2 t = time after injection A 0 = original activity at time t A = activity at time t after decay correction t 1/2 = half-life of 194 h for 131 I and 64 h for 90 Y.
The area under the % ia g -1 over time curve (AUC) was calculated using the trapezoidal rule assuming no activity in the tumour at time 0, and 40% in the blood at time 0. This value for blood was generated from an experiment with both 131 I-labelled A5B7 IgG and F(ab´) 2 , in which blood samples were counted at 30 s postinjection. An average of 39% IgG and 40.7% F(ab´) 2 % ia g -1 was present in the blood at this early time point. This is consistent with the estimated total blood volume of a 20-30 g mouse being in the range 2.0-2.5 ml as described by Durbin et al (1992) . The total decay corrected AUC was converted from % ia g -1 per µCi to MBq g -1 using the following calculation: AUC per 100% × 1000 (for mCi) per 37 (for MBq).
To calculate total β dose to individual organs the MIRD S factor of 0.369 for 131 I and 1.93 for 90 Y (MIRD Pamphlet 11, 1975 ) was used to convert MBq g -1 to cGy h -1 . This calculation does not take into account the contribution of γ energy as most of this penetrating radiation escapes the mouse and there is virtually no self-absorption of γ rays. The calculation also assumes that there is uniform distribution of activity, and there were no cross-organ β radiation doses.
Total β doses to tumour and individual organs were normalized to an equal dose of 100 cGy to the blood. This was achieved by correcting the blood dose to 100 cGy then dividing or multiplying the tissue doses by this correction factor. For example the blood dose of 23 cGy for 131 I-F(ab´) 2 is multiplied by 4.35 to equal 100 cGy, the radiation doses to tumour and normal tissues are multiplied by 4.35 to give the estimated absorbed dose at 100 cGy.
Radioimmunotherapy
To assess the therapeutic potential of DFM and TFM, RIT experiments in the nude mouse xenograft model were designed. The estimated dosimetry calculations were used to predict the total activity of radiolabelled antibodies that should be administered for RIT.
DFM and TFM were radiolabelled with 131 I using the chloramine T method. Free iodine was removed using a PD-10 coloumn, and the percentage incorporation of radiolabel was analysed by thinlayer chromatography (TLC) analysis in 80% methanol. Antigen binding analysis was performed to ensure immunoreactivity was retained, by applying a dilution of the radiolabelled antibody to a 1-ml CEA affinity column and measuring the percentage bound, as described previously by Casey et al (1995) .
Therapy experiments were performed using the same nude mouse model used for the biodistribution experiment described previously (Casey et al, 1996) . Experiments commenced when the LS174T human colon carcinoma xenograft tumours were between 0.1-0.2 cm 3 in volume and in exponential growth (7-10 days after passaging). 18.5 MBq 131 I-TFM and 37 MBq 131 I-DFM were injected intravenously via the tail vein into six mice per group, and a further six untreated mice were used as a control group. Tumours were measured and blood samples were taken (four mice per group) from anaesthetized mice at regular intervals until the white blood cell count (WBC) returned to normal and the tumour volume reached 2 cm 3 , when mice were sacrificed. Four additional mice per group were used for biodistribution, one-tenth of the dose for RIT was administered and 24 h later blood, tumour and tissue samples (liver, kidney, lung, spleen, colon, muscle, femur) were removed for activity assessment in the γ counter.
TFM and IgG were radiolabelled with 90 Y using the method described previously (Casey et al, 1996) . Incorporation was measured by TLC in 0.1 M citrate buffer pH 5.0, and HPLC gel filtration was used to remove any free 90 Y. For RIT 11.1 MBq 90 Y-TFM and 5.6 MBq 90 Y-IgG was injected into six mice per group, six mice were left untreated as a control group. A further four mice were used for a biodistribution experiment as for the 131 I therapy. Tumour measurement and white cell blood counting was also performed as described above.
Statistical comparisons were performed using the MannWhitney U-test for non-parametric statistical analysis.
RESULTS
The data illustrated in Table 1 was generated from comparative biodistribution experiments of 131 I-and 90 Y-labelled A5B7 F(ab´) 2 and DFM, and 131 I-and 90 Y-labelled A5B7 IgG and TFM, which was described in detail previously (Casey et al, 1996) . These figures have been corrected for radioactive decay and were used to calculate estimates of the total absorbed dose to blood, tumour and Table 2 Estimated tissue doses of β-radiation (cGy) per MBq injected activity calculated from the total area under the curve (AUC) using the trapezoidal rule, from the biodistribution data presented in Table 3 Estimated tissue doses of β-radiation (cGy) per MBq injected activity calculated from the total area under the curve (AUC) using the trapezoidal rule, from the biodistribution data described in normal tissues in the nude mouse LS174T human colorectal tumour xenograft model.
Dosimetry
Total absorbed radiation doses were estimated by calculating the AUC for each antibody-radiolabel conjugate and using the MIRD correction factor to convert MBq to absorbed dose in cGy h -1 . These values are illustrated in Tables 2 and 3 .
F(ab´) 2 and DFM
The radiation doses and tumour to blood ratios were similar for F(ab´) 2 and DFM when each was labelled with the same isotope (Table 2) Y-labelled antibody fragments were at least tenfold higher than those delivered by 131 I-labelled antibody fragments. A notable difference between the radionuclides is the high dose to the kidney on radiolabelling with 90 Y (1065-1084 cGy), which is 100 times greater than for 131 I-labelled F(ab´) 2 and DFM (9.73-10.8 cGy). In spite of its size, it is evident that a large proportion of antibody clears through and is retained by the kidney and the toxicity to this organ would severely limit the dose of 90 Y that could be administered for therapy.
The dosimetry calculations also revealed higher absorbed doses for spleen (DFM: 643 cGy, F(ab´) 2 : 327 cGy) and liver (DFM: 387 cGy, F(ab´) 2 : 236 cGy) on administration of 90 Y-DFM compared to 90 Y-F(ab´) 2 . There may be higher non-specific uptake of 90 Y-DFM by the RES that could account for the increase in overall dose to these organs.
IgG and TFM
As found for the F(ab´) 2 and DFM, the radiation dose delivered to all tissues per MBq 90 Y-labelled antibodies was far greater than from the 131 I-labelled antibodies. Radiation doses to blood, tumour and all normal organs were lower on administration of 131 I-TFM compared to 131 I-IgG (Table 3) . This reflects the faster clearance of TFM from the circulation and normal tissues due to the lack of the Fc portion, which is responsible for the long half-life of IgG through FcRn-mediated recycling (Ghetie et al, 1997) . However, this was not observed with 90 Y-TFM; although blood and tumour levels were lower, doses to normal tissues were similar and sometimes greater than for 90 Y-IgG. This is most likely due to retention of 90 Y in cells for longer than 131 I, as has been demonstrated previously (Press et al, 1996) , which contributes largely to the toxicity.
The faster blood clearance of TFM compared to IgG is reflected here in the overall blood doses and tumour to blood ratios (Table 3 ). The bone marrow has been identified as the doselimiting organ in RIT. The clearance rate of radioactivity from the blood has been suggested as a means of predicting bone marrow toxicity (Siegal et al, 1990) , because dose to the marrow equals 0.2-0.4 times that of the blood. Therefore since the blood received approximately half the cumulative dose on administration of 131 I-TFM or 90 Y-TFM compared to IgG conjugates, this will result in a favourable twofold decrease in toxicity to the bone marrow.
Normal tissue toxicity for both iodine labelled IgG and TFM was low and the largest normal tissue dose excluding blood (bone marrow) was to the lungs. Histological studies have demonstrated that A5B7 IgG shows some cross-reactivity with lung tissue (Boxer et al., 1995) , which is possibly due to the presence of low normal levels of CEA produced in the lungs.
The Y-TFM are filtered by the kidney and cleared via this route, which may explain this increase in dose. Conversely, the liver dose for 90 Y-TFM was lower than for 90 Y-IgG which clears largely via the liver. A higher spleen dose was generated on administration of 90 Y-TFM compared to 90 Y-IgG, and this may be due to increased recognition by the RES. Absorbed dose to the bone was also higher for 90 Y-TFM but this level was similar to the absorbed dose by other normal organs such as lung.
Comparative dosimetry of antibodies after blood normalization Radiation dose estimates provided in Table 2 and 3 were normalized to an equal dose (100 cGy) to the blood in Table 4 . Since the levels of radioactivity in the blood has been suggested as a means of predicting bone marrow toxicity (Siegel et al, 1990) this Table, based on an equal blood dose, should reflect the estimated tumour dose and normal tissue toxicity at approximately equal myelotoxic levels. Figure 1 demonstrated efficient tumour localization of both DFM and TFM. Figure 2 shows the mean tumour growth following administration of therapeutic levels of 131 I-DFM and 131 I-TFM compared to a no treatment control group. Both DFM and TFM produced a significant therapeutic effect when compared with the control group (P < 0.05). Tumour growth was delayed for approximately 25 days for both conjugates, and there was no significant difference between the two therapy groups (P > 0.05).
Toxicity was assessed by measurement of white blood cell count (WBC) at weekly intervals until the WBC returned to normal levels ( Figure 3 ). Little toxicity was produced by either DFM or TFM (P > 0.05) and for 2/4 mice from each group the WBC was unaffected after treatment. The remaining 2/4 mice treated with 131 I-DFM and 131 I-TFM showed similar toxicity, with a maximum fall in WBC of > 30% up to 14 days post-therapy. After 21 days the WBC returned to normal for both TFM and DFM (i.e. equivalent or greater than the original pre-therapy figure). Control mice also experienced a decrease in WBC when tumours were approaching 2 cm 3 .
RIT of 90
Y labelled IgG and TFM The blood radiation dose was doubled on administration of the same activity (MBq) of 90 Y-IgG compared to 90 Y-TFM. Assuming the same principle that toxicity is related to total blood dose which in turn reflects absorbed marrow dose, it was predicted that twice the amount of activity of TFM compared to IgG could be administered for the same level of toxicity. An RIT study was designed with reference to dosimetry evaluations and previous therapeutic levels of activity administered for 90 Y-IgG of another antibody A33 (Antoniw et al, 1996) . IgG was labelled to a specific activity of 0.09 MBq µg -1 and TFM to 0.15 MBq µg -1 . Free 90 Y was removed by HPLC purification as described previously (Casey et al, 1996) , and TLC analysis showed > 90% incorporation of radiolabel. Antigen binding analysis post-labelling resulted in 71% binding of IgG and 86% for TFM. Biodistribution at 24 h in Figure 4 demonstrated efficient tumour localization of both IgG and TFM. Toxicity, assessed by WBC (Figure 6 ), was observed for all mice except the control group and lasted up to 21 days. Although predicted to be equal by dosimetry estimates, the overall toxicity was greatest for IgG, resulting in a fall of WBC in all four mice at 14 days to 40% (range 5-40%) of the pre-therapy WBC. For TFM the greatest fall in WBC was observed 7 days post-injection to 30% (range 20-30%). By 14 days recovery of WBC resulted in a return to 70% (range 28-70%) of the original value. At 21 days post-injection there was almost complete recovery of WBC, with the exception of 2/4 mice treated with 90 Y-TFM, which had WBC of 56% and 64% of the original values. This slower return to normal WBC levels is most likely due to the higher dose administered, but there was no significant difference in WBC toxicity between IgG and TFM levels at each time point (P > 0.05).
DISCUSSION
Chemically cross-linked divalent and trivalent versions of the murine antibody A5B7 have shown high stability both in vitro and in nude mice bearing human tumour xenografts (Casey et al, 1996) . In this previous study the cross-linked antibodies showed potential as possible new candidates for RIT, with favourable affinity, biodistribution and tumour uptake coupled with the ability to humanize for reduced immunogenicity. The aim of this study was to measure quantitatively the dose to tumour and normal tissue and to use these estimates to predict the relative doses for use in therapeutic studies. To date only a few studies have considered measurement of radioactivity dose to tissues in model systems, and it is becoming clear that this preclinical data is very important in assessing the level of toxicity to normal tissues compared to the dose to tumour. This is particularly pertinent when the aim is to select optimal combinations of radionuclide and antibody for RIT.
The most prominent difference between the two radionuclides was the increase in dose to all tissues on labelling with 90 Y (Tables 2 and 3 ). Blood doses were 4-6 times higher for divalent antibodies labelled with 90 Y as opposed to 131 I, and 3-4 times higher for TFM and IgG. Similarly tumour levels were five-to sixfold higher than for an equivalent injected dose of 131 I-labelled antibodies. Several other publications (Sharkey et al, 1990; Schott et al, 1992; King et al, 1994) have also reported similar increases in blood and normal tissue levels and tumour retention for 90 Y-labelled antibodies. This resulted in all tumour to blood ratios for 90 Y-labelled antibodies being slightly higher than for 131 I-labelled antibodies. However, when radiation doses estimates were corrected for equitoxic levels to the blood (Table 4) , and the tumour to normal tissues ratios of radiation dose were considered, the ratios for all 90 Y-labelled antibodies were lower than those for 131 I-labelled antibodies. This is an interesting finding, as the biodistribution and dosimetry results had previously favoured use of 90 Y-labelled antibodies based on the higher tumour to blood ratios. For RIT, efficient tumour localization is required to achieve high levels of tumour cell kill, but the corresponding dose to normal tissues is also a major consideration. Since the absorbed dose to normal tissues contributes to overall myelotoxicity, this finding suggests that the maximum tolerated dose in RIT studies will be lower for 90 Y-labelled antibodies than for those labelled with 131 I. The therapeutic effects of 131 I-labelled antibodies were not directly compared here. But in two similar studies it was concluded that, despite the efficacious energy emissions of 90 Y, IgG labelled with 131 I may have equal or better therapeutic prospects than 90 Y-IgG as a consequence of the higher retention of 90 Y-IgG in normal organs Sharkey et al, 1990) .
It is unlikely that the higher radiation dose to the normal tissues after radiolabelling with 90 Y is a product of conjugate instability. It is well known that free 90 Y accumulates in the bone (Harrison et al, 1991) , but the cumulative dose to the bone throughout this study was relatively low and not vastly different to that of other normal tissues, thus reflecting the high stability of the macrocycle conjugate. It is also unlikely that the higher radiation doses of 90 Y-labelled antibodies were due to different distribution of the antibody. The same preparations of antibody fragments were used in each experiment and after radiolabelling immunoreactivity and original size characteristics were retained (Casey et al, 1996) . Therefore the increase in tissue doses of 90 Y-labelled antibodies is most probably due to the higher energy of and greater path length of the pure β-emitter 90 Y, while 90 Y is also known to be retained within cells for longer than 131 I (Press et al, 1996) . The major organs contributing to the increase in absorbed dose of 90 Y-labelled antibodies were the kidney, liver and spleen. The high kidney uptake level for 90 Y-labelled F(ab´) 2 and DFM was first recognized in the previous biodistribution study (Casey et al, 1996) , and here the absorbed dose to the kidney for 90 Y-labelled F(ab´) 2 and DFM was increased by approximately 100-fold compared to their respective 131 I-labelled fragments. Conventional radiotherapy studies have indicated that doses to this organ should not exceed 1500 cGy (Fawwaz et al, 1986) , therefore cumulative kidney doses of 1065 or 1084 cGy MBq In contrast to the divalent fragments, kidney accumulation of 90 Y-TFM was greatly reduced. This is presumably mainly due to the increase in molecular weight, which theoretically restricts passage through the glomerular filter; however, there may be other factors such as shape and charge which also influence the filtration process (Sumpio and Hayslett, 1985 The difference is likely to be concerned with the processing of catabolic products rather than de-iodination. Radiometals such as 90 Y are trapped within lysosomes whereas iodine is more readily released from cells as monoiodotyrosine (Press et al, 1996) . It is also feasible that the higher stability of the thioether bond may slow down catabolism in the kidney tubules, and this effect was higher for 90 Y-TFM due to the retention of this radionuclide within the cells.
High kidney uptake of radiolabelled antibody fragments has been described in several other biodistribution studies, and this effect is more apparent with intracellularly retained radionuclides than with iodine (Sharkey et al, 1990; Behr et al, 1995; Kobayashi et al, 1996) . Current research is being directed into ways of enhancing renal excretion of radiolabelled antibody fragments. One approach is based on blocking kidney tubules with cationic amino acids in order to block anionic sites and inhibit tubular reabsorption of radiolabelled fragments. A fivefold reduction in kidney uptake for 99m Tc-Fab fragments (Behr et al, 1995) and similarly a fivefold reduction for 177 Lu-Fab (DePalatis et al, 1995) has been demonstrated using this approach. Other strategies include modification of the charge of antibody fragments to reduce the pI in attempt to prolong the serum half-life by retarding molecular sieving (Tarburton et al, 1990) or direct uptake by the kidney tubular cells without glomerular filtration. In a recent study by Kobayashi et al (1999) renal accumulation of Fab´ fragments increased significantly as the pI increased (pI 7-9.3). A5B7 F(ab´) 2 and DFM both have a pI of 8, therefore reduction of the pI using techniques such as glycolation could significantly reduce the renal uptake of these fragments.
Liver and splenic uptake levels of 90 Y-labelled antibodies were also elevated. In Tables 2 and 3 , an 18-to 80-fold increase in liver and 10-to 95-fold increase in splenic activity compared to 131 I-labelled antibodies was observed. Both the liver and spleen are organs of the reticuloendothelial system and are involved in the clearance of antibody complexes from the circulation. Therefore it was not surprising that there was a higher absorbed dose to these organs, especially for 90 Y-labelled antibodies due to longer intracellular retention of the radiolabel. Both the liver and spleen are relatively radioresistant organs when compared to the kidney, being able to tolerate much higher doses of radiation before there is a possibility of permanent toxicity damage. However, the contribution to overall myelotoxicity should not be disregarded.
Considering all the combinations of antibody and radionuclide corrected for equitoxic blood levels, the highest tumour to normal tissue ratio of absorbed dose was achieved for 131 I-DFM, suggesting that this would be the optimal combination for RIT. Because other ratios for 131 I-labelled antibodies were only slightly lower than for 131 I-DFM, it was decided to select 131 I-TFM for comparative therapy experiments. The dosimetry estimates were in agreement with RIT results in that twice the activity of 131 I-DFM must be administered in order to produce the same therapeutic effect as 131 I-TFM. This is because the more rapid circulatory clearance of DFM compared to the higher molecular weight TFM results in lower tumour levels for the same injected activity. However, the advantage of this is that the increased tumour to blood ratio produced by DFM enables administration of larger amounts of radioantibody before a similar level of toxicity to the bone marrow is reached. Also, administration of twice the activity of DFM will result in a higher initial dose rate to the tumour, which produces the same inhibition of tumour growth as TFM, although the latter is retained in the tumour for longer. Toxicity measured by WBC in this study was minimal, implying that larger doses of both 131 I-DFM and 131 I-TFM may be administered to produce longer tumour regression or complete cures.
Despite the improved tumour:blood ratios for TFM, the increased estimated dose to normal tissues suggested that the most promising combination with the radionuclide 90 Y appeared to be IgG. This is contrary to the conclusion reached in the previous publication that 90 Y-TFM is optimal, based simply on the improved tumour to blood ratios for the biodistribution experiment (Casey et al, 1996) . This confirms the importance of comparing radiation dose ratios for tumour and normal tissues as well as those for blood. After correction for equitoxic blood levels, dosimetry revealed that doses to normal tissues were in fact twice the level of IgG, producing a twofold increase in the overall tumour to normal tissue ratio. This indicates that 90 Y-IgG is a more suitable alternative to 90 Y-TFM. 90 Y-TFM administered at twice the activity of 90 Y-IgG produced slightly less WBC toxicity, but also a lower therapeutic response. This indicates that higher levels of administered activity of 90 Y-TFM are required to produce a similar growth delay to 90 Y-IgG, but will most likely produce higher toxicity as predicted by the dosimetry calculations. Ultimately the higher residence time of 90 Y-TFM in normal tissues had a negative effect by increasing toxicity, thus reducing the total dose that may be safely administered therapeutically.
There are certain advantages of antibody fragments that should not be disregarded when selecting the most appropriate targeting entity. The Fc portion of the antibody is effectively redundant in terms of antibody binding of a carrier molecule and is also the most immunogenic part of an antibody. Thus removal of the Fc does not generally compromise immunoreactivity but does reduce overall immunogenicity. Antibody fragments are also known to be advantageous in terms of increased speed of tumour penetration, which can result in delivery of a dose that is more evenly distributed throughout the tumour mass . Tumour penetration was not compared in this study, but a similar recent report by Antoniw et al (1996) demonstrated more rapid penetration of A33 TFM compared to A33 IgG.
Recent studies have focused on measurements of the microdistribution of radiolabelled antibodies within tumours. Using phosphor plate technology (Johnson et al, 1990 ), a threedimensional tumour dosimetry model has been designed to measure microscopic dose measurements to study the distribution of radiolabelled antibodies and fragments within tumours over time (Flynn et al, 1998) . A potential application of this and other similar models is to study the importance of binding affinity in areas of low or high antigen density within tumours. Initial experiments comparing the biodistribution of radiolabelled DFM and F(ab´) 2 within tumour sections (xenografts) have implied that DFM was retained in viable areas of the tumour for longer than F(ab´) 2 , which was more evenly distributed throughout cellular and necrotic regions. This could be explained by the increase in functional affinity of DFM and may have implications for improved RIT.
In the previous study DFM and TFM also demonstrated faster on-rates and slower off-rates than F(ab´) 2 and IgG (Casey et al, 1996) . Since human tumours are known to have a more heterogeneous distribution of antigen compared to most human xenograft tumours, higher affinity may be advantageous in terms of improved binding to areas of low antigen density (Sung et al, 1992) . Future microdosimetric analysis may reveal the true potential of improved on and off-rates for DFM and TFM in human tumours, which may further assist in selection of antibody and radionuclide for future clinical trials.
The results described here on the basis of the highest tumour to normal tissue dose ratio at equitoxic blood levels, suggests that DFM labelled with 131 I is the best combination of antibody and radionuclide for future RIT. This is consistent with the conclusions in the previous publication which indicated that DFM radiolabelled with 131 I would be optimal, due to a significantly faster
